revealed excellent synergistic effects of the combination of the GAS6/AXL axis inhibitor SLC-391 with venetoclax treatment on inhibiting AML stem/progenitor cell proliferation and long-term clonal activity. This evidence concerns the gene GAS6 and acute myeloid leukemia.